NCT06795906View on ClinicalTrials.gov

A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions
Asthma
Interventions
DRUG

AZD8630

AZD8630 will be administered via dry powder inhalation (DPI).

OTHER

Placebo

Placebo will be administered via DPI.

DEVICE

Saphira device

AZD8630 or placebo will be administered to participants via Saphira device.

Trial Locations (3)

10119

Research Site, Berlin

22926

Research Site, Ahrensburg

55128

Research Site, Mainz

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT06795906 - A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma | Biotech Hunter | Biotech Hunter